SCHEDULE: Venrock Group Amends Abivax SA Stake to 0.8%
Beneficial Ownership Amendment
A group of Venrock entities and individuals have filed an amendment to their Schedule 13G, disclosing a beneficial ownership of 0.8% of Abivax SA's ordinary shares as of September 30, 2025.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
- The Reporting Persons collectively beneficially own 576,729 ordinary shares of Abivax SA.
- This ownership represents 0.8% of Abivax SA's outstanding ordinary shares.
- The beneficial ownership is reported as of September 30, 2025.
- The percentage is calculated based on 73,574,749 ordinary shares of Abivax SA outstanding as of July 28, 2025, as reported in the Issuer's prospectus supplement dated July 23, 2025.
- The ownership consists of 151,622 ordinary shares in the form of American Depositary Shares (ADSs) directly held by VHCP III, 15,167 ordinary shares in the form of ADSs directly held by VHCP Co-Investment III, and 409,940 ordinary shares in the form of ADSs directly held by VHCP EG.
- Each ADS represents one ordinary share.
- The Reporting Persons share both voting and dispositive power over the 576,729 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of Abivax SA.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership, not containing performance or forward-looking statements that would indicate positive or negative sentiment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor group in a biotechnology company. It does not provide specific industry-related analysis or context beyond the ownership stake itself.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in Abivax SA.
- Investment Community: Offers insight into institutional holdings, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2023-11-22 | Date of previous Schedule 13G filing for incorporated by reference exhibits. |
| 2025-07-23 | Date of Abivax SA's prospectus supplement. |
| 2025-07-24 | Date Abivax SA's prospectus supplement was filed with the SEC. |
| 2025-07-28 | Date for which 73,574,749 ordinary shares of Abivax SA were reported outstanding. |
| 2025-09-30 | Date of event which requires filing of this statement (beneficial ownership reported as of this date). |
| 2025-11-14 | Date the Schedule 13G/A was signed. |
Keywords
Abivax SA, Venrock, Schedule 13G, beneficial ownership, ordinary shares, ADSs, institutional ownership, biotech, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.